BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Rating of “Moderate Buy” by Analysts

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $24.80.

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. started coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 target price on the stock. UBS Group cut shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research report on Wednesday, July 8th. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Oppenheimer assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Finally, Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $23.00 target price for the company.

BridgeBio Oncology Therapeutics Price Performance

BBOT opened at $8.82 on Friday. The firm’s fifty day moving average price is $8.20. The stock has a market cap of $706.57 million, a price-to-earnings ratio of -4.30 and a beta of 0.39. BridgeBio Oncology Therapeutics has a one year low of $7.00 and a one year high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. Research analysts forecast that BridgeBio Oncology Therapeutics will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Large investors have recently modified their holdings of the company. Tema ETFs LLC lifted its position in BridgeBio Oncology Therapeutics by 13.6% in the 2nd quarter. Tema ETFs LLC now owns 93,339 shares of the company’s stock worth $711,000 after buying an additional 11,167 shares during the last quarter. Avidity Partners Management LP bought a new stake in shares of BridgeBio Oncology Therapeutics in the 1st quarter worth approximately $392,000. Granahan Investment Management LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics in the 1st quarter valued at $2,068,000. Renaissance Technologies LLC boosted its stake in shares of BridgeBio Oncology Therapeutics by 37.1% in the 1st quarter. Renaissance Technologies LLC now owns 101,900 shares of the company’s stock valued at $912,000 after purchasing an additional 27,600 shares in the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after purchasing an additional 5,249 shares during the last quarter. 54.89% of the stock is owned by hedge funds and other institutional investors.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.